Effects of afatinib through other target proteins than EGFR
碩士 === 國立臺灣大學 === 生化科學研究所 === 106 === Afatinib (BIBW 2992, Gilotrif™, Giotrif®) is a drug developed by Boehringer Ingelheim to treat non-small cell lung cancer as targeted therapy. Afatinib can act as an irreversible covalent inhibitor of the tyrosine kinases in the ErbB family (EGFR, HER2, HER4), w...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | zh-TW |
| Published: |
2018
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/h6qshd |